Causaly launches AI platform to support scientific work across drug development
Causaly has introduced a new tool designed to help life sciences researchers plan and complete complex research tasks, from target selection to clinical development.
Causaly has launched Causaly Work, an AI-powered tool intended to help life sciences researchers carry out the work involved in research and development decisions.
The platform is designed to take on broader objectives than answering individual scientific questions. Users describe the task they want to complete, such as ranking drug targets, assessing a potential biomarker or comparing previous clinical trials, and can provide their own data alongside publicly available sources.
Causaly Work then plans the research, selects methods and coordinates the analysis, producing outputs that researchers can review and share with colleagues.
The launch adds another capability to Causaly’s existing platform, which also includes Agentic Research and Scientific Workflows. The company said the new tool is intended for open-ended research objectives where the approach needs to be developed to fit the problem, rather than following an established process.
Planning and carrying out research
Causaly said the platform creates a research plan before beginning work. This sets out the methods selected, why they were chosen, alternative approaches considered, assumptions and evidence gaps, and the criteria used to assess the results.
Specialised AI agents then research and validate methods before coordinating the work needed to complete the plan. The platform can use scientific tools and computational analysis to produce reports, ranked tables, figures, notebooks, presentations and interactive dashboards.
The company said researchers can inspect the code used in the analysis, which runs in a private workspace. Conclusions are linked to scientific literature and Causaly’s biomedical knowledge graph, allowing teams to examine the evidence and calculations behind the outputs.
The approach is intended to make the reasoning and methods behind an analysis more transparent, rather than simply presenting researchers with an answer. Causaly said this could help teams assess a wider range of options when making decisions about development programmes.
A different role from existing Causaly tools
Causaly Work joins two other capabilities within the company’s platform, each designed for a different type of scientific task.
Agentic Research is designed to answer scientific questions using cited evidence, while Scientific Workflows support established processes that experts have already defined, including standard operating procedures and other recurring work.
Causaly Work, by contrast, is aimed at less structured objectives, including exploratory analysis and research where the methods and evaluation criteria need to be determined for each task. All three capabilities draw on the same scientific evidence base.
“High-stakes decisions in a development program depend on understanding every option, and the work to evaluate those options rarely follows a fixed script,” said Yiannis Kiachopoulos, co-founder and CEO of Causaly. “Causaly Work adapts to the problem in front of it, so scientists can finally explore the paths they once set aside for lack of time. It widens the set of options and evaluates each one across the dimensions that matter, giving the people at the decision gate a fuller picture to judge from.”
The launch comes as life sciences R&D teams increasingly explore how AI can support evidence assessment and data analysis. Causaly’s proposition is that coordinating these activities within a single platform could help researchers complete more of the work required to inform decisions, while retaining the ability to examine the methods and evidence behind the results.




